-
1
-
-
0035424844
-
Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study
-
Saylors RL 3rd, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:3463-3469.
-
(2001)
J Clin Oncol
, vol.19
, pp. 3463-3469
-
-
Saylors III, R.L.1
Stine, K.C.2
Sullivan, J.3
-
2
-
-
18744413524
-
Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-A report from the Intergroup Rhabdomyosarcoma Study IV
-
Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-A report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003;21:78-84.
-
(2003)
J Clin Oncol
, vol.21
, pp. 78-84
-
-
Breneman, J.C.1
Lyden, E.2
Pappo, A.S.3
-
3
-
-
0036250461
-
Treatment of refractory osteosarcoma with fractionated Cyclophosphamide and etoposide
-
Rodriguez-Galindo C, Daw NC, Kaste SC, et al. Treatment of refractory osteosarcoma with fractionated Cyclophosphamide and etoposide. J Pediatr Hematol Oncol 2002;24:250-255.
-
(2002)
J Pediatr Hematol Oncol
, vol.24
, pp. 250-255
-
-
Rodriguez-Galindo, C.1
Daw, N.C.2
Kaste, S.C.3
-
4
-
-
0042914721
-
CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin lymphoma
-
Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin lymphoma. J Clin Oncol 2003;21:3041-3050.
-
(2003)
J Clin Oncol
, vol.21
, pp. 3041-3050
-
-
Doorduijn, J.K.1
Van Der Holt, B.2
Van Imhoff, G.W.3
-
5
-
-
0037687355
-
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
-
Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
-
(2003)
J Clin Oncol
, vol.21
, pp. 1431-1439
-
-
Citron, M.L.1
Berry, D.A.2
Cirrincione, C.3
-
6
-
-
0029863162
-
Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients
-
Slattery JT, Kalhorn TF, McDonald GB, et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996;14:1484-1494.
-
(1996)
J Clin Oncol
, vol.14
, pp. 1484-1494
-
-
Slattery, J.T.1
Kalhorn, T.F.2
McDonald, G.B.3
-
8
-
-
1842844017
-
Pharmacological Considerations of Primary Alkylators
-
Andersson B, Murray D, editors. Boston: Kluwer Academic Publishers
-
McCune JS, Slattery JT. Pharmacological Considerations of Primary Alkylators. In: Andersson B, Murray D, editors. Clinically relevant resistance in cancer chemotherapy. Boston: Kluwer Academic Publishers; 2002. p 323-337.
-
(2002)
Clinically Relevant Resistance in Cancer Chemotherapy
, pp. 323-337
-
-
McCune, J.S.1
Slattery, J.T.2
-
9
-
-
0026100542
-
Clinical pharmacokinetics of cyclophosphamide
-
Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1991;20:194-208.
-
(1991)
Clin Pharmacokinet
, vol.20
, pp. 194-208
-
-
Moore, M.J.1
-
11
-
-
0017264779
-
The metabolism of cyclophosphamide. Dose dependency and the effect of long-term treatment with cyclophosphamide
-
Mouridsen HT, Faber O, Skovsted L. The metabolism of cyclophosphamide. Dose dependency and the effect of long-term treatment with cyclophosphamide. Cancer 1976;37:665-670.
-
(1976)
Cancer
, vol.37
, pp. 665-670
-
-
Mouridsen, H.T.1
Faber, O.2
Skovsted, L.3
-
12
-
-
0028801467
-
Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation [published erratum appears in Cancer Res 1995 Apr 1;55(7):1600]
-
Chen TL, Passos-Coelho JL, Noe DA, et al. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation [published erratum appears in Cancer Res 1995 Apr 1;55(7):1600]. Cancer Res 1995;55:810-816.
-
(1995)
Cancer Res
, vol.55
, pp. 810-816
-
-
Chen, T.L.1
Passos-Coelho, J.L.2
Noe, D.A.3
-
13
-
-
0031657664
-
Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients
-
Ren S, Kalhorn TF, McDonald GB, et al. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Clin Pharmacol Ther 1998;64:289-301.
-
(1998)
Clin Pharmacol Ther
, vol.64
, pp. 289-301
-
-
Ren, S.1
Kalhorn, T.F.2
McDonald, G.B.3
-
14
-
-
0030799414
-
Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes
-
Ren S, Yang JS, Kalhorn TF, et al. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 1997;57:4229-4235
-
(1997)
Cancer Res
, vol.57
, pp. 4229-4235
-
-
Ren, S.1
Yang, J.S.2
Kalhorn, T.F.3
-
15
-
-
0026667068
-
Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde
-
Dockham PA, Lee MO, Sladek NE. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem Pharmacol 1992;43:2453-2469.
-
(1992)
Biochem Pharmacol
, vol.43
, pp. 2453-2469
-
-
Dockham, P.A.1
Lee, M.O.2
Sladek, N.E.3
-
16
-
-
0026751449
-
Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients
-
Tasso MJ, Boddy AV, Price L, et al. Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. Cancer Chemother Pharmacol 1992;30:207-211.
-
(1992)
Cancer Chemother Pharmacol
, vol.30
, pp. 207-211
-
-
Tasso, M.J.1
Boddy, A.V.2
Price, L.3
-
17
-
-
0042912912
-
Clinical and cellular pharmacology in relation to solid tumours of childhood
-
Estlin EJ, Veal GJ. Clinical and cellular pharmacology in relation to solid tumours of childhood. Cancer Treat Rev 2003;29:253-273.
-
(2003)
Cancer Treat Rev
, vol.29
, pp. 253-273
-
-
Estlin, E.J.1
Veal, G.J.2
-
18
-
-
0037370735
-
Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation
-
McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003;101:2043-2048.
-
(2003)
Blood
, vol.101
, pp. 2043-2048
-
-
McDonald, G.B.1
Slattery, J.T.2
Bouvier, M.E.3
-
19
-
-
0842311624
-
Cyclophosphamide metabolism in children with non-Hodgkin lymphoma
-
Yule SM, Price L, McMahon AD, et al. Cyclophosphamide metabolism in children with non-Hodgkin lymphoma. Clin Cancer Res 2004;10:455-460.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 455-460
-
-
Yule, S.M.1
Price, L.2
McMahon, A.D.3
-
20
-
-
0016705622
-
Pharmacokinetics of cyclophosphamide in renal failure
-
Mouridsen HT, Jacobsen E. Pharmacokinetics of cyclophosphamide in renal failure. Acta Pharmacol Toxicol 1975;36:409-414.
-
(1975)
Acta Pharmacol Toxicol
, vol.36
, pp. 409-414
-
-
Mouridsen, H.T.1
Jacobsen, E.2
-
21
-
-
0019440332
-
Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites
-
Juma FD, Rogers HJ, Trounce JR. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol 1981;19:443-451.
-
(1981)
Eur J Clin Pharmacol
, vol.19
, pp. 443-451
-
-
Juma, F.D.1
Rogers, H.J.2
Trounce, J.R.3
-
22
-
-
0018596314
-
The disposition of cyclophosphamide in a group of myeloma patients
-
Bramwell V, Calvert RT, Edwards G, et al. The disposition of cyclophosphamide in a group of myeloma patients. Cancer Chemother Pharmacol 1979;3:253-259.
-
(1979)
Cancer Chemother Pharmacol
, vol.3
, pp. 253-259
-
-
Bramwell, V.1
Calvert, R.T.2
Edwards, G.3
-
23
-
-
0036226436
-
Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency
-
Haubitz M, Bohnenstengel F, Brunkhorst R, et al. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 2002;61:1495-1501.
-
(2002)
Kidney Int
, vol.61
, pp. 1495-1501
-
-
Haubitz, M.1
Bohnenstengel, F.2
Brunkhorst, R.3
-
24
-
-
0031715170
-
Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous leukemia and renal failure on hemodialysis
-
Bischoff ME, Blau W, Wagner T, et al. Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous leukemia and renal failure on hemodialysis. Bone Marrow Transplant 1998;22:591-593.
-
(1998)
Bone Marrow Transplant
, vol.22
, pp. 591-593
-
-
Bischoff, M.E.1
Blau, W.2
Wagner, T.3
-
25
-
-
0032951656
-
Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease
-
Perry JJ, Fleming RA, Rocco MV, et al. Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease. Bone Marrow Transplant 1999;23:839-842.
-
(1999)
Bone Marrow Transplant
, vol.23
, pp. 839-842
-
-
Perry, J.J.1
Fleming, R.A.2
Rocco, M.V.3
-
26
-
-
0017855921
-
Haemodialysis during cyclophosphamide treatment
-
Bending MR, Finch RE. Haemodialysis during cyclophosphamide treatment. Br Med J 1978;1:1145-1146.
-
(1978)
Br Med J
, vol.1
, pp. 1145-1146
-
-
Bending, M.R.1
Finch, R.E.2
-
27
-
-
0019491166
-
Clearance and recovery calculations in hemodialysis: Application to plasma, red blood cells, and dialysate measurements for cyclophosphamide
-
Wang LH, Lee CS, Majeske BL, et al. Clearance and recovery calculations in hemodialysis: Application to plasma, red blood cells, and dialysate measurements for cyclophosphamide. Clin Pharmacol Ther 1981;29:365-372.
-
(1981)
Clin Pharmacol Ther
, vol.29
, pp. 365-372
-
-
Wang, L.H.1
Lee, C.S.2
Majeske, B.L.3
-
28
-
-
2042537638
-
Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites
-
German
-
Wagner T, Heydrich D, Bartels H, et al. [Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites]. Arzneimittelforschung 1980;30:1588-1592. German.
-
(1980)
Arzneimittelforschung
, vol.30
, pp. 1588-1592
-
-
Wagner, T.1
Heydrich, D.2
Bartels, H.3
-
29
-
-
0028609968
-
Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508
-
Chan KK, Hong PS, Tutsch K, et al. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508. Cancer Res 1994;54:6421-6429.
-
(1994)
Cancer Res
, vol.54
, pp. 6421-6429
-
-
Chan, K.K.1
Hong, P.S.2
Tutsch, K.3
-
30
-
-
0030223023
-
Cyclophosphamide and 4-Hydroxycyclophosphamide/Aldophosphamide kinetics in patients receiving high-dose Cyclophosphamide chemotherapy
-
Anderson LW, Chen TL, Colvin OM, et al. Cyclophosphamide and 4-Hydroxycyclophosphamide/Aldophosphamide kinetics in patients receiving high-dose Cyclophosphamide chemotherapy. Clin Cancer Res 1996;2:1481-1487.
-
(1996)
Clin Cancer Res
, vol.2
, pp. 1481-1487
-
-
Anderson, L.W.1
Chen, T.L.2
Colvin, O.M.3
-
31
-
-
0031934032
-
Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: A Pediatric Oncology Group Study
-
Saylors RL 3rd, Stewart CF, Zamboni WC, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: A Pediatric Oncology Group Study. J Clin Oncol 1998;16:945-952.
-
(1998)
J Clin Oncol
, vol.16
, pp. 945-952
-
-
Saylors III, R.L.1
Stewart, C.F.2
Zamboni, W.C.3
-
32
-
-
0032846456
-
Analysis of cyclophosphamide and five metabolites from human plasma using liquid chromatography-mass spectrometry and gas chromatography-nitrogen- phosphorus detection
-
Kalhorn TF, Ren S, Howald WN, et al. Analysis of cyclophosphamide and five metabolites from human plasma using liquid chromatography-mass spectrometry and gas chromatography-nitrogen-phosphorus detection. J Chromatogr B Biomed Sci Appl 1999;732:287-298.
-
(1999)
J Chromatogr B Biomed Sci Appl
, vol.732
, pp. 287-298
-
-
Kalhorn, T.F.1
Ren, S.2
Howald, W.N.3
-
34
-
-
0037370735
-
Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation
-
McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003;101:2043-2048.
-
(2003)
Blood
, vol.101
, pp. 2043-2048
-
-
McDonald, G.B.1
Slattery, J.T.2
Bouvier, M.E.3
-
35
-
-
14444271073
-
Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer
-
Gilbert CJ, Petros WP, Vredenburgh J, et al. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol 1998;42:497-503.
-
(1998)
Cancer Chemother Pharmacol
, vol.42
, pp. 497-503
-
-
Gilbert, C.J.1
Petros, W.P.2
Vredenburgh, J.3
-
36
-
-
0032801763
-
Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics
-
Cagnoni PJ, Matthes S, Day TC, et al. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant 1999;24:1-4.
-
(1999)
Bone Marrow Transplant
, vol.24
, pp. 1-4
-
-
Cagnoni, P.J.1
Matthes, S.2
Day, T.C.3
-
37
-
-
0028890757
-
Cyclophosphamide metabolism in children
-
Yule SM, Boddy AV, Cole M, et al. Cyclophosphamide metabolism in children. Cancer Res 1995;55:803-809.
-
(1995)
Cancer Res
, vol.55
, pp. 803-809
-
-
Yule, S.M.1
Boddy, A.V.2
Cole, M.3
-
38
-
-
0034743355
-
Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion
-
Yule SM, Price L, Cole M, et al. Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion. Cancer Chemother Pharmacol 2001;47:222-228.
-
(2001)
Cancer Chemother Pharmacol
, vol.47
, pp. 222-228
-
-
Yule, S.M.1
Price, L.2
Cole, M.3
-
39
-
-
0033736153
-
In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone
-
McCune JS, Hawke RL, LeCluyse EL, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 2000;68:356-366.
-
(2000)
Clin Pharmacol Ther
, vol.68
, pp. 356-366
-
-
McCune, J.S.1
Hawke, R.L.2
LeCluyse, E.L.3
-
40
-
-
0017837582
-
Haemodialysis during cyclophosphamide treatment
-
Milsted RA, Jarman M. Haemodialysis during cyclophosphamide treatment. Br Med J 1978;1:820-821.
-
(1978)
Br Med J
, vol.1
, pp. 820-821
-
-
Milsted, R.A.1
Jarman, M.2
-
41
-
-
0030045849
-
Cyclophosphamide pharmacokinetics in children
-
Yule SM, Boddy AV, Cole M, et al. Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol 1996;41:13-19.
-
(1996)
Br J Clin Pharmacol
, vol.41
, pp. 13-19
-
-
Yule, S.M.1
Boddy, A.V.2
Cole, M.3
|